| 0.4732 -0.008 (-1.58%) | 10-27 00:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.46 | 1-year : | 0.55 |
| Resists | First : | 0.39 | Second : | 0.47 |
| Pivot price | 0.35  |
|||
| Supports | First : | 0.27 | Second : | 0.22 |
| MAs | MA(5) : | 0.31 |
MA(20) : | 0.36 |
| MA(100) : | 0.51 |
MA(250) : | 0.72 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 28.1  |
D(3) : | 26.6 |
| RSI | RSI(14): 27.9 |
|||
| 52-week | High : | 1.98 | Low : | 0.27 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GBS ] has closed above bottom band by 14.7%. Bollinger Bands are 4.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.33 - 0.33 | 0.33 - 0.33 |
| Low: | 0.29 - 0.3 | 0.3 - 0.3 |
| Close: | 0.31 - 0.31 | 0.31 - 0.31 |
GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Tue, 06 Feb 2024
ET GBS: How to craft strategies for navigating economic challenges the world is facing - The Economic Times
Fri, 20 Oct 2023
Global Business Services (GBS): The Future of Shared Services - Zinnov
Tue, 10 Oct 2023
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS) - Yahoo Finance
Mon, 11 Sep 2023
SSON Research & Analytics Announces Winners of 2023 Top 20 Most Admired SSOs & GBS - The Shared Services & Outsourcing Network
Mon, 10 Jul 2023
Top GBS employers provide learning pitch, career path - The Times of India
Tue, 02 May 2023
Where business support functions leaders can pull ahead in 2023 - McKinsey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 1.347e+007 (%) |
| Held by Institutions | 9 (%) |
| Shares Short | 112 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 907.1 % |
| Return on Equity (ttm) | -30.5 % |
| Qtrly Rev. Growth | 437150 % |
| Gross Profit (p.s.) | 0.13 |
| Sales Per Share | 0.13 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 2.32 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 151860 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|